Skip to search formSkip to main contentSkip to account menu

ICRF 154

Known as: ICRF-154 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
After the identification of a new lead bisphenol compound that had good topoisomerase IIα (EC 5.99.1.3) inhibitory activity, a… 
2008
2008
SummaryWe studied the antitumor activity of newly synthesized bis(1-acyloxymethyl) derivatives of 4,4′-(1,2-ethanediyl)bis(2,6… 
2003
2003
Abstract A Chinese hamster V79 cell-based assay for detection of topoisomerase II (topo II) poisons and catalytic inhibitors has… 
1999
1999
MST-16 [4,4-1,2-(ethanediyl)bis(1-isobutoxycarbonyl-oxy-methyl-2,6-pipera zinedione)], recently approved as an oral anticancer… 
1998
1998
MST-16, a derivative of bis(2,6-dioxopiperazine), is a newly developed anticancer agent that is potentially effective in… 
1994
1994
Internucleosomal DNA fragmentation and cell death were induced dose- and time-dependently by incubation of mouse thymocytes with… 
1989
1989
Many N1-acyloxymethyl derivatives VI of bis(2,6-dioxopiperazine) I, ICRF-154, were prepared and tested for antitumor activity… 
1984
1984
X-ray diffraction studies of crystals from samples of bimolane synthesized in China and in the United States showed that the…